Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Geographic Atrophy Secondary to Age-related Macular Degeneration”

82 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 82 results

Early research (Phase 1)Study completedNCT04246866
What this trial is testing

First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration

Who this might be right for
Dry Age-related Macular DegenerationGeographic AtrophyMacular Degeneration+2 more
Gemini Therapeutics, Inc. 12
Not applicableLooking for participantsNCT07144137
What this trial is testing

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

Who this might be right for
Geographic Atrophy Secondary to Age-related Macular Degeneration
Complement Therapeutics 75
Not applicableLooking for participantsNCT06662162
What this trial is testing

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration

Who this might be right for
Age-Related Macular DegenerationAge-related Macular Degeneration (ARMD)Intermediate AMD+1 more
i-Lumen Scientific AUS PTY LTD 100
Testing effectiveness (Phase 2)Looking for participantsNCT07174687
What this trial is testing

SGLT2 Inhibitors in Geographic Atrophy

Who this might be right for
Retinal DegenerationRetinal DiseasesEye Diseases+2 more
Washington University School of Medicine 70
Early research (Phase 1)Study completedNCT04014777
What this trial is testing

Study of NGM621 in Participants With Geographic Atrophy

Who this might be right for
Geographic Atrophy
NGM Biopharmaceuticals, Inc 15
Early research (Phase 1)Ended earlyNCT04002310
What this trial is testing

Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy

Who this might be right for
Macular Degeneration
Boehringer Ingelheim 18
Large-scale testing (Phase 3)Study completedNCT02686658
What this trial is testing

Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Who this might be right for
Geographic AtrophyDry Age-Related Macular Degeneration
IVERIC bio, Inc. 286
Testing effectiveness (Phase 2)Active Not RecruitingNCT06018558
What this trial is testing

Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy

Who this might be right for
Geographic Atrophy
Ocugen 60
Testing effectiveness (Phase 2)Study completedNCT04465955
What this trial is testing

NGM621 in Participants With Geographic Atrophy

Who this might be right for
Geographic Atrophy
NGM Biopharmaceuticals, Inc 320
Not applicableActive Not RecruitingNCT06161584
What this trial is testing

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Who this might be right for
Geographic Atrophy
Apellis Pharmaceuticals, Inc. 300
Large-scale testing (Phase 3)Active Not RecruitingNCT06510816
What this trial is testing

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA)

Who this might be right for
Geographic Atrophy
Annexon, Inc. 659
Large-scale testing (Phase 3)Ended earlyNCT02247479
What this trial is testing

A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Who this might be right for
Geographic Atrophy
Hoffmann-La Roche 906
Not applicableEnded earlyNCT02479386
What this trial is testing

Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Who this might be right for
Geographic Atrophy
Hoffmann-La Roche 296
Large-scale testing (Phase 3)Study completedNCT04005352
What this trial is testing

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

Who this might be right for
Age-related Macular Degeneration
Novartis Pharmaceuticals 734
Not applicableUnknownNCT05391074
What this trial is testing

Oral Postbiotics in Patients With Macular Atrophy

Who this might be right for
Geographic AtrophyAge-Related Macular Degeneration
Institut de la Macula y la Retina 10
Testing effectiveness (Phase 2)Looking for participantsNCT06635148
What this trial is testing

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Who this might be right for
Geographic AtrophyMacular Degeneration
Janssen Research & Development, LLC 274
Testing effectiveness (Phase 2)Ended earlyNCT04437368
What this trial is testing

EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Who this might be right for
Dry Age-related Macular Degeneration
Gyroscope Therapeutics Limited 98
Early research (Phase 1)Study completedNCT04615325
What this trial is testing

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Who this might be right for
Geographic Atrophy
Hoffmann-La Roche 37
Testing effectiveness (Phase 2)Study completedNCT03815825
What this trial is testing

GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Who this might be right for
Macular DegenerationGeographic Atrophy
Ionis Pharmaceuticals, Inc. 332
Large-scale testing (Phase 3)Study completedNCT07214740
What this trial is testing

Study to Evaluate a Pegcetacoplan (Syfovre®) Prefilled Syringe

Who this might be right for
Geographic Atrophy Secondary to Age-related Macular Degeneration
Apellis Pharmaceuticals, Inc. 44
Load More Results